News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Conference News European Congress on Obesity 2025 SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly Michael O'Riordan May 14, 2025
News Conference News THT 2025 Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Todd Neale February 12, 2025
News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News EACTS 2024 Will Semaglutide Change Cardiac Surgery? It Already Has Yael L. Maxwell October 10, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Features Obesity and COVID-19: Theories and Blame Fill the Scientific Void Shelley Wood April 21, 2020
News Daily News Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook L.A. McKeown August 04, 2016
News Daily News Anti-Inflammatory Drug Does Not Halt Plaque Progression in Overweight Patients With CAD Todd Neale May 27, 2016